Thursday, 2 December 2021

Australia's most trusted
source of pharma news

Thursday, 02 December 2021

Drugs that flunked in 2021

Posted 24 November 2021 AM

It's been a year of disappointment for some Australian pharmas with 14 major drugs either rejected or deferred by PBAC so far in 2021, with the fate of another four from November's meeting, hanging in the balance. 

An analysis by Pharma in Focus examined "new listing" submissions made to the committee's meetings in March, May, July and September and considered drugs which were resubmitted to the PBAC's last major meeting of the year, and its upcoming intracycle meeting in December.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.